- In December 2023, Gilead Sciences, Inc. announced U.S. FDA has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy
- In May 2022, Bristol-Myers Squibb Company announced the approval of Opdivo plus Yervoy as a first line treatment for adult patients by Japan's Ministry of Health, Labour and Welfare. This may help the company to strengthen its product portfolio
- In February 2022, the FDA has approved CARVYKTI (ciltacabtagene autoleucel) from Janssen for treating adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, marking Janssen's inaugural cell therapy. This will underscore the dedication to advance their oncology treatment options
- In December 2021, Novartis AG has signed an agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), enhancing the company's immuno-oncology Research and development. This collaboration contributes to Novartis Oncology's broader initiative to advance innovation in cancer treatments by incorporating a potentially transformative therapy into its expanding immunotherapy platform
